Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Rectal Neoplasms 2Neoplasms 2Waldenstrom Macroglobulinemia 1Prostatic Neoplasms 1Paraproteinemias 1Lung Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Oxaliplatin 180Capecitabine 174Fluorouracil 154Radiotherapy 107Leucovorin 107Irinotecan 93Bevacizumab 69Surgical Procedures, Operative 49Cetuximab 39Drug Therapy 38Radiation 35Neoadjuvant Therapy 33Folfox protocol 29Chemoradiotherapy 29XELOX 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 21Radiotherapy, Intensity-Modulated 19Surveys and Questionnaires 17Proctectomy 16Biopsy 16Early Intervention, Educational 14trifluridine tipiracil drug combination 12Panitumumab 12Floxuridine 12tislelizumab 11regorafenib 11Nivolumab 11Laparoscopy 11Celecoxib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Rectal Neoplasms × Rifaximin × Clear all
NCT06783153 2025-01-20

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Mansoura University

Phase 1/2 Not yet recruiting
80 enrolled
GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

NCT01345175 2024-05-14

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
69 enrolled 9 charts
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡